Abstract
Niacin treatment (alone) was compared with etofibrate and niacin combination to treat patients with high-density lipoprotein <35 mg/dl and without hypertriglyceridemia. The niacin and etofibrate combination proved to be safe and increased high-density lipoprotein cholesterol levels to 48%, which was 3 times higher than that obtained with niacin alone.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Anticholesteremic Agents / administration & dosage
-
Anticholesteremic Agents / therapeutic use*
-
Cholesterol, HDL / blood*
-
Clofibric Acid / administration & dosage
-
Clofibric Acid / analogs & derivatives*
-
Clofibric Acid / therapeutic use
-
Coronary Disease / blood
-
Coronary Disease / drug therapy*
-
Delayed-Action Preparations
-
Drug Administration Schedule
-
Drug Synergism
-
Female
-
Humans
-
Lipids / blood
-
Male
-
Middle Aged
-
Niacin / administration & dosage
-
Niacin / therapeutic use*
-
Time Factors
-
Treatment Outcome
Substances
-
Anticholesteremic Agents
-
Cholesterol, HDL
-
Delayed-Action Preparations
-
Lipids
-
etofibrate
-
Niacin
-
Clofibric Acid